Skip to main content
. 2017 Nov 22;12:184. doi: 10.1186/s13014-017-0910-0

Table 3.

Overall and recurrence-free survival according to patient characteristics and treatment variables

Characteristic 5-year overall survival (p-value) 5-year recurrence-free survival
Sex
 Male 51.4% (0.539) 56.7% (0.826)
 Female 50% 75%
Age
 < 40 years 100% (0.136) 100% (0.19)
 ≧ 40 years 49.1% 56.9%
Smoking
 Yes 51.5% (0.536) 57.2% (0.91)
 No 50% 66.7%
Alcohol
 Yes 55.5% (0.311) 57.6% (0.575)
 No 35.7% 72.7%
Betel quid
 Yes 42.2% (0.068) 50.8% (0.154)
 No 71.1% 75.9%
Anemia
 Yes 29.2% (0.002)* 54% (0.106)
 No 60.2% 61%
Differentiation
 Poor 40% (0.752) 30% (0.03)*
 Well or moderate 53.1% 64%
pT stage
 pT4 52.9% (0.978) 64% (0.461)
 pT1–3 48% 50%
pN stage
 N1 55.3% (0.481) 62.7% (0.34)
 N0 48.4% 53.8%
Surgical margin
 ≤ 4 mm 48.2% (0.791) 59.8% (0.587)
 > 4 mm 56% 57.6%
Skin invasion
 Yes 59.3% (0.485) 64.6% (0.428)
 No 48.9% 57.1%
Bone invasion
 Yes 46.4% (0.44) 55.4% (0.396)
 No 55% 61.7%
Perineural invasion
 Yes 51.2% (0.953) 58.8% (0.723)
 No 50.2% 59.2%
Vascular invasion
 Yes 60% (0.444) 60% (0.785)
 No 48.8% 57%
Lymphatic invasion
 Yes 50% (0.948) 50% (0.752)
 No 51.2% 59.1%
Invasion depth
 ≥ 11 mm 52.1% (0.432) 69.2% (0.177)
 < 11 mm 42.9% 57.1%
RT technique
 Other 47.2% (0.623) 51.7% (0.489)
 IMRT 56.1% 78.3%
RT duration
 > 8 weeks 28.6% (0.07) 28.6% (0.063)
 ≤ 8 weeks 53.7% 62.3%
Time between OP & RT
 > 6 weeks 42% (0.192) 48.2% (0.38)
 ≤ 6 weeks 57% 65.5%
RT Dose
 < 6600 cGy 39.2% (0.065) 50.8% (0.191)
 6600 cGy 73.9% 73.7%
Concurrent chemotherapy
 No 35.3% (0.018)* 426% (0.009)*
 Yes 67.2% 75.4%

*Statistically significant in the multivariate analysis, p < 0.05

Abbreviations: RT radiotherapy, IMRT intensity-modulated radiotherapy, OP operation